Chicago Equity Partners LLC acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,510 shares of the biopharmaceutical company’s stock, valued at approximately $675,000.

A number of other large investors have also bought and sold shares of the stock. Alpha Windward LLC boosted its stake in Regeneron Pharmaceuticals by 0.3% during the second quarter. Alpha Windward LLC now owns 384 shares of the biopharmaceutical company’s stock valued at $189,000 after buying an additional 1 shares during the period. Regentatlantic Capital LLC boosted its stake in Regeneron Pharmaceuticals by 0.9% during the second quarter. Regentatlantic Capital LLC now owns 537 shares of the biopharmaceutical company’s stock valued at $264,000 after buying an additional 5 shares during the period. Capital Planning Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 2.1% during the second quarter. Capital Planning Advisors LLC now owns 582 shares of the biopharmaceutical company’s stock valued at $286,000 after buying an additional 12 shares during the period. Sequoia Financial Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 1.7% during the second quarter. Sequoia Financial Advisors LLC now owns 712 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 12 shares during the period. Finally, Princeton Capital Management Inc. boosted its stake in Regeneron Pharmaceuticals by 0.6% during the second quarter. Princeton Capital Management Inc. now owns 2,511 shares of the biopharmaceutical company’s stock valued at $1,233,000 after buying an additional 15 shares during the period. 67.80% of the stock is owned by institutional investors.

In other news, major shareholder Sanofi bought 166,415 shares of Regeneron Pharmaceuticals stock in a transaction on Thursday, August 24th. The shares were purchased at an average price of $480.93 per share, for a total transaction of $80,033,965.95. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Robert E. Landry sold 189 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total value of $94,700.34. Following the transaction, the chief financial officer now owns 10,099 shares in the company, valued at approximately $5,060,204.94. The disclosure for this sale can be found here. Insiders have sold a total of 61,460 shares of company stock worth $29,143,390 in the last quarter. Company insiders own 10.80% of the company’s stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ REGN) opened at $394.69 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $340.09 and a twelve month high of $543.55. The company has a current ratio of 3.63, a quick ratio of 3.07 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $41,392.43, a P/E ratio of 33.45, a price-to-earnings-growth ratio of 1.52 and a beta of 1.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported $3.99 earnings per share for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The firm had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter in the prior year, the business earned $3.13 EPS. The business’s revenue for the quarter was up 23.0% on a year-over-year basis. sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 13.55 earnings per share for the current fiscal year.

REGN has been the subject of several research analyst reports. UBS AG reissued a “buy” rating and set a $535.00 price objective (up previously from $489.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 4th. Citigroup Inc. lifted their price objective on Regeneron Pharmaceuticals from $555.00 to $575.00 and gave the company a “buy” rating in a research note on Friday, August 4th. Canaccord Genuity set a $522.00 price objective on Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 3rd. Bank of America Corporation reaffirmed a “buy” rating and set a $593.00 price target (up previously from $589.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, July 21st. Finally, Credit Suisse Group reaffirmed a “buy” rating and set a $485.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, September 11th. Two research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $475.34.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/11/17/1510-shares-in-regeneron-pharmaceuticals-inc-regn-acquired-by-chicago-equity-partners-llc.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.